Lantern Pharma (NASDAQ:LTRN – Get Free Report) and International Stem Cell (OTCMKTS:ISCO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.
Institutional & Insider Ownership
28.6% of Lantern Pharma shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 71.8% of International Stem Cell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Lantern Pharma has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, International Stem Cell has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lantern Pharma | 1 | 0 | 0 | 0 | 1.00 |
| International Stem Cell | 0 | 0 | 0 | 0 | 0.00 |
Valuation and Earnings
This table compares Lantern Pharma and International Stem Cell”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lantern Pharma | N/A | N/A | -$17.12 million | ($1.45) | -1.81 |
| International Stem Cell | $9.10 million | 0.23 | -$420,000.00 | ($0.06) | -4.43 |
International Stem Cell has higher revenue and earnings than Lantern Pharma. International Stem Cell is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Lantern Pharma and International Stem Cell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lantern Pharma | N/A | -198.34% | -129.08% |
| International Stem Cell | -4.78% | N/A | -8.55% |
Summary
International Stem Cell beats Lantern Pharma on 6 of the 11 factors compared between the two stocks.
About Lantern Pharma
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
About International Stem Cell
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
